| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 49 | 2024 | 2325 | 3.550 |
Why?
|
| Islets of Langerhans Transplantation | 24 | 2008 | 739 | 1.900 |
Why?
|
| Kidney Transplantation | 39 | 2022 | 4215 | 1.800 |
Why?
|
| Transplantation, Heterologous | 28 | 2022 | 2379 | 1.760 |
Why?
|
| Tissue and Organ Procurement | 13 | 2024 | 944 | 1.730 |
Why?
|
| Islets of Langerhans | 17 | 2005 | 1345 | 1.470 |
Why?
|
| Organ Transplantation | 8 | 2024 | 1150 | 1.370 |
Why?
|
| Graft Survival | 28 | 2022 | 3794 | 1.260 |
Why?
|
| Tissue Donors | 18 | 2024 | 2313 | 1.180 |
Why?
|
| Liver Failure | 7 | 2021 | 249 | 1.070 |
Why?
|
| Graft Rejection | 32 | 2022 | 4426 | 1.060 |
Why?
|
| Perfusion | 4 | 2024 | 1376 | 1.010 |
Why?
|
| Bibliometrics | 2 | 2024 | 351 | 0.860 |
Why?
|
| Brain Death | 6 | 2021 | 356 | 0.850 |
Why?
|
| Immunosuppressive Agents | 24 | 2022 | 4166 | 0.820 |
Why?
|
| Antigens, Heterophile | 5 | 2020 | 70 | 0.790 |
Why?
|
| Swine | 18 | 2022 | 5899 | 0.790 |
Why?
|
| Liver, Artificial | 1 | 2021 | 55 | 0.770 |
Why?
|
| Organ Preservation | 9 | 2024 | 379 | 0.640 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 4 | 2015 | 506 | 0.640 |
Why?
|
| Genes, bcl-2 | 6 | 2004 | 119 | 0.620 |
Why?
|
| Mycophenolic Acid | 11 | 2011 | 343 | 0.610 |
Why?
|
| Physicians, Women | 1 | 2024 | 495 | 0.600 |
Why?
|
| Animals, Genetically Modified | 13 | 2022 | 1553 | 0.590 |
Why?
|
| Tacrolimus | 7 | 2018 | 733 | 0.570 |
Why?
|
| Chemoembolization, Therapeutic | 5 | 2016 | 127 | 0.560 |
Why?
|
| Estradiol | 5 | 2005 | 1932 | 0.560 |
Why?
|
| Reperfusion Injury | 8 | 2012 | 1023 | 0.490 |
Why?
|
| Papio | 9 | 2022 | 661 | 0.470 |
Why?
|
| Kidney Diseases | 4 | 2021 | 2093 | 0.460 |
Why?
|
| Living Donors | 4 | 2020 | 636 | 0.460 |
Why?
|
| Double-Balloon Enteroscopy | 1 | 2013 | 7 | 0.460 |
Why?
|
| Alabama | 12 | 2019 | 104 | 0.450 |
Why?
|
| Diabetes Mellitus, Experimental | 11 | 2005 | 1112 | 0.440 |
Why?
|
| Carcinoma, Hepatocellular | 11 | 2024 | 2299 | 0.430 |
Why?
|
| Gene Transfer Techniques | 7 | 2004 | 1204 | 0.430 |
Why?
|
| Antibodies, Heterophile | 5 | 2021 | 128 | 0.420 |
Why?
|
| Periodicals as Topic | 1 | 2024 | 1469 | 0.420 |
Why?
|
| Dilatation | 1 | 2013 | 307 | 0.390 |
Why?
|
| Pancreas Transplantation | 11 | 2004 | 196 | 0.380 |
Why?
|
| Patient Selection | 8 | 2021 | 4283 | 0.360 |
Why?
|
| Authorship | 2 | 2024 | 281 | 0.360 |
Why?
|
| Liver | 14 | 2020 | 7509 | 0.350 |
Why?
|
| Cholestasis | 1 | 2013 | 377 | 0.350 |
Why?
|
| Liver Neoplasms | 12 | 2024 | 4319 | 0.350 |
Why?
|
| Immunoglobulin G | 8 | 2018 | 4541 | 0.340 |
Why?
|
| Professional-Family Relations | 1 | 2013 | 495 | 0.330 |
Why?
|
| Waiting Lists | 6 | 2021 | 763 | 0.330 |
Why?
|
| Donor Selection | 3 | 2021 | 228 | 0.330 |
Why?
|
| Liver Cirrhosis | 6 | 2017 | 1931 | 0.320 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2019 | 1355 | 0.320 |
Why?
|
| Adenoviridae | 8 | 2007 | 1084 | 0.320 |
Why?
|
| Specialization | 1 | 2013 | 778 | 0.310 |
Why?
|
| Inflammation Mediators | 5 | 2003 | 1881 | 0.300 |
Why?
|
| Liver Diseases | 5 | 2021 | 1302 | 0.280 |
Why?
|
| Kidney | 12 | 2022 | 7064 | 0.270 |
Why?
|
| End Stage Liver Disease | 2 | 2021 | 353 | 0.260 |
Why?
|
| Physicians | 1 | 2024 | 4591 | 0.260 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2021 | 1827 | 0.260 |
Why?
|
| Cytokines | 10 | 2010 | 7343 | 0.240 |
Why?
|
| Hepatitis C | 4 | 2018 | 1579 | 0.240 |
Why?
|
| Protein C | 1 | 2004 | 133 | 0.230 |
Why?
|
| Animals | 62 | 2022 | 167963 | 0.230 |
Why?
|
| Glomerulonephritis | 1 | 2006 | 337 | 0.230 |
Why?
|
| Monkey Diseases | 1 | 2004 | 71 | 0.230 |
Why?
|
| Humans | 112 | 2024 | 760621 | 0.220 |
Why?
|
| Social Class | 1 | 2012 | 2005 | 0.220 |
Why?
|
| Histocompatibility | 3 | 2021 | 316 | 0.220 |
Why?
|
| Male | 84 | 2024 | 359744 | 0.220 |
Why?
|
| Yttrium Radioisotopes | 1 | 2024 | 107 | 0.220 |
Why?
|
| Survival Analysis | 12 | 2021 | 10182 | 0.210 |
Why?
|
| Haplorhini | 1 | 2004 | 529 | 0.210 |
Why?
|
| Polylysine | 1 | 2003 | 131 | 0.210 |
Why?
|
| Gene Knockout Techniques | 4 | 2020 | 802 | 0.210 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2018 | 1446 | 0.210 |
Why?
|
| Immunotoxins | 8 | 2003 | 175 | 0.210 |
Why?
|
| Apoptosis | 10 | 2005 | 9501 | 0.210 |
Why?
|
| Nitric Oxide | 3 | 2014 | 2141 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2005 | 1246 | 0.210 |
Why?
|
| Macaca mulatta | 17 | 2018 | 2316 | 0.210 |
Why?
|
| Family | 1 | 2013 | 3189 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2003 | 225 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 5 | 2019 | 9185 | 0.200 |
Why?
|
| Galactosyltransferases | 3 | 2019 | 276 | 0.200 |
Why?
|
| Health Services Accessibility | 6 | 2019 | 5397 | 0.200 |
Why?
|
| Carbohydrates | 2 | 2021 | 388 | 0.190 |
Why?
|
| Portal Vein | 2 | 2003 | 429 | 0.190 |
Why?
|
| Stents | 1 | 2013 | 3314 | 0.190 |
Why?
|
| Hepatic Artery | 1 | 2002 | 230 | 0.180 |
Why?
|
| Microspheres | 1 | 2024 | 787 | 0.180 |
Why?
|
| Ureterostomy | 1 | 2000 | 18 | 0.180 |
Why?
|
| Endoplasmic Reticulum | 2 | 2005 | 1132 | 0.180 |
Why?
|
| Mice, SCID | 8 | 2005 | 2627 | 0.180 |
Why?
|
| Cystostomy | 1 | 2000 | 25 | 0.180 |
Why?
|
| Oligopeptides | 2 | 2003 | 1187 | 0.180 |
Why?
|
| Genetic Vectors | 7 | 2007 | 3380 | 0.180 |
Why?
|
| Postoperative Complications | 12 | 2021 | 15697 | 0.180 |
Why?
|
| Insulin | 12 | 2004 | 6597 | 0.180 |
Why?
|
| Renal Insufficiency | 1 | 2006 | 820 | 0.170 |
Why?
|
| Simvastatin | 1 | 2002 | 352 | 0.170 |
Why?
|
| Chi-Square Distribution | 6 | 2016 | 3465 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 1 | 10 | 2004 | 3455 | 0.160 |
Why?
|
| Kidney Failure, Chronic | 3 | 2021 | 2471 | 0.160 |
Why?
|
| Primates | 3 | 2019 | 523 | 0.160 |
Why?
|
| Middle Aged | 46 | 2024 | 220352 | 0.160 |
Why?
|
| Aneurysm | 1 | 2002 | 337 | 0.160 |
Why?
|
| Guanidines | 5 | 2003 | 193 | 0.160 |
Why?
|
| Cytoprotection | 3 | 2005 | 200 | 0.150 |
Why?
|
| Retrospective Studies | 35 | 2024 | 80372 | 0.150 |
Why?
|
| Immunoglobulin M | 2 | 2020 | 1529 | 0.150 |
Why?
|
| Female | 61 | 2024 | 391270 | 0.150 |
Why?
|
| Life Support Care | 1 | 2019 | 222 | 0.150 |
Why?
|
| Gastric Antral Vascular Ectasia | 1 | 2017 | 6 | 0.150 |
Why?
|
| Models, Animal | 3 | 2019 | 2117 | 0.150 |
Why?
|
| Caspases | 4 | 2005 | 878 | 0.150 |
Why?
|
| Treatment Outcome | 26 | 2024 | 65017 | 0.140 |
Why?
|
| Urinary Bladder | 5 | 1995 | 1166 | 0.140 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2017 | 63 | 0.140 |
Why?
|
| Adult | 39 | 2024 | 219994 | 0.140 |
Why?
|
| Endothelium, Vascular | 3 | 2003 | 4433 | 0.130 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2018 | 377 | 0.130 |
Why?
|
| United States | 13 | 2024 | 72461 | 0.130 |
Why?
|
| Mixed Function Oxygenases | 1 | 2017 | 265 | 0.130 |
Why?
|
| Transplantation Immunology | 1 | 1998 | 532 | 0.130 |
Why?
|
| Health Care Rationing | 1 | 2018 | 435 | 0.130 |
Why?
|
| Time Factors | 24 | 2021 | 40165 | 0.130 |
Why?
|
| Organ Preservation Solutions | 3 | 2003 | 100 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 4899 | 0.120 |
Why?
|
| Rats, Inbred Lew | 3 | 2012 | 1154 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 3442 | 0.120 |
Why?
|
| Drug Therapy, Combination | 9 | 2021 | 6498 | 0.120 |
Why?
|
| Drainage | 6 | 1995 | 1161 | 0.120 |
Why?
|
| Sirolimus | 2 | 2021 | 1547 | 0.120 |
Why?
|
| Risk Adjustment | 1 | 2018 | 601 | 0.120 |
Why?
|
| Enzyme Activation | 4 | 2005 | 3602 | 0.120 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2016 | 1200 | 0.120 |
Why?
|
| Cold Ischemia | 1 | 2015 | 67 | 0.120 |
Why?
|
| Peritoneovenous Shunt | 1 | 1994 | 9 | 0.120 |
Why?
|
| Lymphocele | 1 | 1994 | 19 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 8056 | 0.120 |
Why?
|
| Amebiasis | 1 | 2014 | 33 | 0.120 |
Why?
|
| Mice, Inbred NOD | 3 | 2003 | 1837 | 0.120 |
Why?
|
| Bile Ducts | 1 | 2015 | 282 | 0.120 |
Why?
|
| Lung Transplantation | 3 | 2021 | 1305 | 0.110 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 3388 | 0.110 |
Why?
|
| Tissue Survival | 2 | 2003 | 119 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2018 | 805 | 0.110 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2013 | 177 | 0.110 |
Why?
|
| Arteries | 1 | 2018 | 1126 | 0.110 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2013 | 86 | 0.110 |
Why?
|
| Transportation | 1 | 2015 | 214 | 0.110 |
Why?
|
| Histocompatibility Testing | 4 | 2019 | 717 | 0.110 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 18137 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2006 | 4357 | 0.110 |
Why?
|
| Epitopes | 1 | 2019 | 2503 | 0.110 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 604 | 0.100 |
Why?
|
| Sodium Nitrite | 1 | 2012 | 16 | 0.100 |
Why?
|
| Organizational Policy | 1 | 2015 | 429 | 0.100 |
Why?
|
| Shock, Hemorrhagic | 1 | 2014 | 223 | 0.100 |
Why?
|
| B-Lymphocytes | 4 | 2022 | 4742 | 0.100 |
Why?
|
| Logistic Models | 4 | 2016 | 13314 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2016 | 6544 | 0.100 |
Why?
|
| Coronary Artery Bypass | 1 | 2001 | 2272 | 0.090 |
Why?
|
| Policy Making | 1 | 2015 | 538 | 0.090 |
Why?
|
| Cadaver | 4 | 2003 | 1345 | 0.090 |
Why?
|
| Marital Status | 1 | 2012 | 433 | 0.090 |
Why?
|
| Mice | 20 | 2007 | 81208 | 0.090 |
Why?
|
| Transplantation, Homologous | 12 | 2003 | 4810 | 0.090 |
Why?
|
| Immune Tolerance | 7 | 2003 | 2299 | 0.090 |
Why?
|
| Allopurinol | 4 | 2012 | 198 | 0.090 |
Why?
|
| Aged | 19 | 2024 | 169152 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 4490 | 0.090 |
Why?
|
| Cell Nucleus | 3 | 2003 | 2907 | 0.090 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2001 | 1582 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2021 | 1869 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 1131 | 0.090 |
Why?
|
| Decision Making | 2 | 2014 | 3925 | 0.090 |
Why?
|
| Sus scrofa | 2 | 2021 | 433 | 0.090 |
Why?
|
| Risk Assessment | 7 | 2021 | 24123 | 0.090 |
Why?
|
| Cell Death | 3 | 2007 | 1672 | 0.090 |
Why?
|
| Smad Proteins | 1 | 2010 | 156 | 0.080 |
Why?
|
| I-kappa B Proteins | 1 | 2010 | 212 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 1796 | 0.080 |
Why?
|
| NF-kappa B | 3 | 2010 | 2488 | 0.080 |
Why?
|
| Catheterization | 2 | 2013 | 1432 | 0.080 |
Why?
|
| Polyethylene Glycols | 2 | 2005 | 1189 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 9 | 2005 | 22023 | 0.080 |
Why?
|
| Muromonab-CD3 | 2 | 1999 | 104 | 0.080 |
Why?
|
| Transplantation Tolerance | 2 | 2003 | 605 | 0.080 |
Why?
|
| Fatty Liver | 2 | 2012 | 778 | 0.080 |
Why?
|
| Creatinine | 5 | 2004 | 1903 | 0.080 |
Why?
|
| Raffinose | 3 | 2003 | 53 | 0.070 |
Why?
|
| Anemia | 1 | 2017 | 1511 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2006 | 2913 | 0.070 |
Why?
|
| Necrosis | 4 | 2014 | 1612 | 0.070 |
Why?
|
| Caspase 12 | 2 | 2005 | 8 | 0.070 |
Why?
|
| Risk Factors | 13 | 2021 | 74359 | 0.070 |
Why?
|
| Medically Uninsured | 1 | 2013 | 843 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 3334 | 0.070 |
Why?
|
| Intestinal Mucosa | 2 | 2010 | 3022 | 0.070 |
Why?
|
| Gastric Mucosa | 1 | 2010 | 599 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 1998 | 275 | 0.070 |
Why?
|
| Helicobacter pylori | 1 | 2010 | 377 | 0.070 |
Why?
|
| Methylprednisolone | 5 | 2000 | 384 | 0.070 |
Why?
|
| Graft vs Host Disease | 2 | 2018 | 3025 | 0.070 |
Why?
|
| Helicobacter Infections | 1 | 2010 | 386 | 0.070 |
Why?
|
| T-Lymphocytes | 5 | 2018 | 10181 | 0.070 |
Why?
|
| Blood Glucose | 8 | 2005 | 6381 | 0.070 |
Why?
|
| Survival Rate | 8 | 2015 | 12808 | 0.070 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 39261 | 0.060 |
Why?
|
| Cause of Death | 2 | 2013 | 3725 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 4013 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 1407 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 1173 | 0.060 |
Why?
|
| Phenylbutyrates | 1 | 2005 | 72 | 0.060 |
Why?
|
| Reoperation | 5 | 2015 | 4291 | 0.060 |
Why?
|
| Macrophages | 3 | 2010 | 5745 | 0.060 |
Why?
|
| Cells, Cultured | 5 | 2018 | 18957 | 0.060 |
Why?
|
| Cell Survival | 3 | 2004 | 5797 | 0.060 |
Why?
|
| Educational Status | 1 | 2012 | 2515 | 0.060 |
Why?
|
| Glutathione | 3 | 2003 | 582 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2010 | 1032 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2014 | 1343 | 0.060 |
Why?
|
| Gene Expression | 4 | 2012 | 7588 | 0.060 |
Why?
|
| Transplantation, Isogeneic | 1 | 2004 | 248 | 0.060 |
Why?
|
| Hepacivirus | 2 | 2011 | 1334 | 0.060 |
Why?
|
| Cyclosporine | 4 | 2000 | 777 | 0.060 |
Why?
|
| Pancreas, Artificial | 1 | 2005 | 54 | 0.060 |
Why?
|
| Stromal Cells | 2 | 2006 | 1326 | 0.060 |
Why?
|
| Trypsinogen | 2 | 1994 | 84 | 0.060 |
Why?
|
| Caspase 8 | 1 | 2004 | 189 | 0.060 |
Why?
|
| Surface-Active Agents | 1 | 2004 | 150 | 0.060 |
Why?
|
| Warm Ischemia | 1 | 2024 | 58 | 0.060 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2003 | 45 | 0.060 |
Why?
|
| Income | 1 | 2012 | 1875 | 0.060 |
Why?
|
| Age Factors | 5 | 2019 | 18416 | 0.060 |
Why?
|
| Brefeldin A | 1 | 2003 | 68 | 0.060 |
Why?
|
| Streptozocin | 1 | 2004 | 194 | 0.060 |
Why?
|
| Calcimycin | 1 | 2003 | 213 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2011 | 1031 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1991 | 1928 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5201 | 0.050 |
Why?
|
| Tunicamycin | 1 | 2003 | 108 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2003 | 1385 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2006 | 698 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2006 | 657 | 0.050 |
Why?
|
| Thrombosis | 3 | 2003 | 3052 | 0.050 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 122 | 0.050 |
Why?
|
| Urologic Diseases | 3 | 1994 | 248 | 0.050 |
Why?
|
| Culture Techniques | 1 | 2003 | 530 | 0.050 |
Why?
|
| Medicaid | 1 | 2016 | 2815 | 0.050 |
Why?
|
| Biopsy | 5 | 2011 | 6771 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2012 | 2062 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2003 | 285 | 0.050 |
Why?
|
| bcl-Associated Death Protein | 1 | 2002 | 102 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 2 | 2010 | 1959 | 0.050 |
Why?
|
| Neutrophils | 3 | 2005 | 3767 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2002 | 185 | 0.050 |
Why?
|
| Adenosine | 3 | 2003 | 834 | 0.050 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 12531 | 0.050 |
Why?
|
| Bioethics | 1 | 2004 | 117 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 2003 | 1763 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 575 | 0.050 |
Why?
|
| Length of Stay | 5 | 2015 | 6479 | 0.050 |
Why?
|
| Fas Ligand Protein | 1 | 2002 | 215 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 755 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2004 | 731 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 728 | 0.050 |
Why?
|
| Hepatectomy | 2 | 2005 | 559 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2021 | 2493 | 0.050 |
Why?
|
| Iliac Vein | 1 | 2002 | 70 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 1 | 2003 | 321 | 0.050 |
Why?
|
| Transfection | 5 | 2002 | 5781 | 0.050 |
Why?
|
| Neuraminic Acids | 1 | 2021 | 16 | 0.050 |
Why?
|
| Elapid Venoms | 1 | 2021 | 41 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2013 | 1939 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 444 | 0.050 |
Why?
|
| Quercetin | 1 | 2002 | 97 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2006 | 820 | 0.050 |
Why?
|
| Propensity Score | 2 | 2021 | 1928 | 0.050 |
Why?
|
| Oncolytic Virotherapy | 1 | 2007 | 515 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 5508 | 0.050 |
Why?
|
| Preoperative Care | 3 | 2005 | 2256 | 0.050 |
Why?
|
| Monocytes | 2 | 2010 | 2575 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 491 | 0.050 |
Why?
|
| Arginine | 1 | 2004 | 934 | 0.050 |
Why?
|
| Cercopithecidae | 1 | 2020 | 22 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2013 | 2501 | 0.050 |
Why?
|
| Transcription Factors | 4 | 2005 | 12103 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2003 | 586 | 0.050 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2000 | 44 | 0.050 |
Why?
|
| Iliac Artery | 1 | 2002 | 344 | 0.050 |
Why?
|
| Rats | 3 | 2012 | 23711 | 0.050 |
Why?
|
| Hemobilia | 1 | 2000 | 18 | 0.040 |
Why?
|
| Dendritic Cells | 2 | 2010 | 2725 | 0.040 |
Why?
|
| Transplantation, Heterotopic | 1 | 2000 | 174 | 0.040 |
Why?
|
| Common Bile Duct | 1 | 2000 | 106 | 0.040 |
Why?
|
| Choledochostomy | 1 | 2000 | 15 | 0.040 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2000 | 75 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2010 | 5496 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 886 | 0.040 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 1999 | 24 | 0.040 |
Why?
|
| Antilymphocyte Serum | 1 | 2021 | 482 | 0.040 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2000 | 120 | 0.040 |
Why?
|
| Multivariate Analysis | 5 | 2014 | 12159 | 0.040 |
Why?
|
| Primate Diseases | 1 | 1999 | 15 | 0.040 |
Why?
|
| Mitochondria | 2 | 2002 | 3600 | 0.040 |
Why?
|
| Cholangitis | 1 | 2000 | 113 | 0.040 |
Why?
|
| Cholecystitis | 1 | 2000 | 181 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2004 | 810 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2002 | 430 | 0.040 |
Why?
|
| Biliary Tract Diseases | 1 | 2000 | 157 | 0.040 |
Why?
|
| Virus Replication | 1 | 2007 | 2432 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2014 | 6238 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2010 | 8313 | 0.040 |
Why?
|
| Tissue Preservation | 1 | 1999 | 174 | 0.040 |
Why?
|
| Glucose | 3 | 2002 | 4351 | 0.040 |
Why?
|
| Recovery of Function | 3 | 2003 | 2985 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2001 | 782 | 0.040 |
Why?
|
| Technetium Tc 99m Pentetate | 2 | 1995 | 67 | 0.040 |
Why?
|
| Biological Transport | 1 | 2002 | 2086 | 0.040 |
Why?
|
| Anastomosis, Surgical | 3 | 2015 | 983 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1999 | 465 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2004 | 1513 | 0.040 |
Why?
|
| Health Maintenance Organizations | 1 | 2000 | 660 | 0.040 |
Why?
|
| Cost Control | 1 | 2000 | 630 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2007 | 1801 | 0.040 |
Why?
|
| Intestines | 1 | 2006 | 1907 | 0.040 |
Why?
|
| Azathioprine | 1 | 1999 | 356 | 0.040 |
Why?
|
| Transplants | 1 | 2019 | 206 | 0.040 |
Why?
|
| Inflammation | 3 | 2014 | 10756 | 0.040 |
Why?
|
| Liver Function Tests | 2 | 2014 | 524 | 0.040 |
Why?
|
| Diphtheria Toxin | 2 | 2000 | 252 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2006 | 11071 | 0.030 |
Why?
|
| Antibodies | 2 | 2022 | 2421 | 0.030 |
Why?
|
| Adolescent | 9 | 2014 | 87810 | 0.030 |
Why?
|
| Death | 1 | 2021 | 678 | 0.030 |
Why?
|
| Hemofiltration | 1 | 1996 | 59 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2003 | 1336 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 4573 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 1998 | 365 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 1997 | 255 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2002 | 3094 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2000 | 8555 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2003 | 5039 | 0.030 |
Why?
|
| Temperature | 1 | 2002 | 2221 | 0.030 |
Why?
|
| Prothrombin Time | 1 | 1995 | 116 | 0.030 |
Why?
|
| Pancreatic Ducts | 1 | 1997 | 329 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 5785 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2002 | 1485 | 0.030 |
Why?
|
| Hemostatics | 1 | 1998 | 243 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2000 | 705 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2002 | 1612 | 0.030 |
Why?
|
| Platelet Transfusion | 2 | 2014 | 294 | 0.030 |
Why?
|
| Cross Reactions | 1 | 2017 | 818 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 1 | 1995 | 205 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1998 | 377 | 0.030 |
Why?
|
| Ammonia | 1 | 1995 | 236 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 6538 | 0.030 |
Why?
|
| Endoscopy, Digestive System | 1 | 2017 | 351 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2005 | 1870 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2000 | 1016 | 0.030 |
Why?
|
| Hemoglobins | 2 | 2017 | 1521 | 0.030 |
Why?
|
| Urography | 1 | 1995 | 312 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2002 | 10827 | 0.030 |
Why?
|
| Hirschsprung Disease | 1 | 1996 | 163 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 1995 | 416 | 0.030 |
Why?
|
| Prednisone | 1 | 1999 | 1565 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2014 | 1832 | 0.030 |
Why?
|
| Recurrence | 3 | 2015 | 8482 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2002 | 2448 | 0.030 |
Why?
|
| Antioxidants | 1 | 2002 | 1667 | 0.030 |
Why?
|
| Bilirubin | 1 | 1995 | 438 | 0.030 |
Why?
|
| Registries | 3 | 2019 | 8469 | 0.030 |
Why?
|
| Capsules | 1 | 2014 | 192 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2018 | 726 | 0.030 |
Why?
|
| Glucose Tolerance Test | 3 | 2003 | 1175 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2019 | 8035 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 2 | 2014 | 566 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 7806 | 0.030 |
Why?
|
| Biliary Atresia | 1 | 1993 | 88 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2002 | 2864 | 0.030 |
Why?
|
| Macaca fascicularis | 3 | 2000 | 900 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 1998 | 2852 | 0.030 |
Why?
|
| Urethral Diseases | 1 | 1993 | 53 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 600 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 2180 | 0.030 |
Why?
|
| Health Care Costs | 3 | 2015 | 3258 | 0.030 |
Why?
|
| Resource Allocation | 1 | 2015 | 349 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 1995 | 865 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1995 | 674 | 0.030 |
Why?
|
| Postoperative Care | 2 | 2002 | 1479 | 0.030 |
Why?
|
| Minority Groups | 1 | 2019 | 1201 | 0.030 |
Why?
|
| Hip Fractures | 1 | 2000 | 989 | 0.020 |
Why?
|
| Nitrites | 1 | 2012 | 159 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2015 | 1098 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 3707 | 0.020 |
Why?
|
| Risk | 1 | 2004 | 9631 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2014 | 9716 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2017 | 1368 | 0.020 |
Why?
|
| SEER Program | 1 | 2016 | 1530 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1998 | 1328 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2012 | 271 | 0.020 |
Why?
|
| Theophylline | 1 | 1991 | 131 | 0.020 |
Why?
|
| Drug Approval | 1 | 2018 | 816 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2017 | 5870 | 0.020 |
Why?
|
| Fetal Tissue Transplantation | 1 | 1991 | 137 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 9530 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2007 | 12293 | 0.020 |
Why?
|
| Prognosis | 3 | 2024 | 29658 | 0.020 |
Why?
|
| Aortic Valve | 1 | 2001 | 1996 | 0.020 |
Why?
|
| Benzoates | 1 | 2012 | 212 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 961 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2003 | 2758 | 0.020 |
Why?
|
| Phytohemagglutinins | 2 | 2001 | 168 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2014 | 1636 | 0.020 |
Why?
|
| Phenotype | 2 | 2018 | 16546 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2014 | 20509 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2002 | 4938 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2000 | 3735 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 1791 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2000 | 1913 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2014 | 1895 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1998 | 2145 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2006 | 22053 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 1 | 1999 | 2660 | 0.020 |
Why?
|
| Colon | 1 | 1996 | 1788 | 0.020 |
Why?
|
| Alleles | 1 | 2019 | 6898 | 0.020 |
Why?
|
| Intestine, Small | 1 | 1994 | 1207 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 2001 | 2065 | 0.020 |
Why?
|
| Child | 7 | 2015 | 79806 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 5791 | 0.020 |
Why?
|
| Organ Size | 2 | 2005 | 2254 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 15289 | 0.020 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2007 | 73 | 0.020 |
Why?
|
| Cohort Studies | 4 | 2015 | 41335 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1993 | 814 | 0.020 |
Why?
|
| Dogs | 4 | 1992 | 3841 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1999 | 2543 | 0.020 |
Why?
|
| Cold Temperature | 2 | 2000 | 780 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2001 | 5990 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 1993 | 1168 | 0.020 |
Why?
|
| Thrombelastography | 2 | 1998 | 183 | 0.020 |
Why?
|
| Imidazoles | 1 | 2012 | 1180 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1993 | 1889 | 0.020 |
Why?
|
| Genes, Reporter | 2 | 2002 | 1529 | 0.020 |
Why?
|
| Hemodynamics | 2 | 2012 | 4174 | 0.020 |
Why?
|
| Dermis | 1 | 2007 | 202 | 0.020 |
Why?
|
| Transcription Factor CHOP | 1 | 2005 | 68 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 1998 | 3598 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2006 | 522 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2003 | 5889 | 0.020 |
Why?
|
| Mice, Nude | 1 | 1991 | 3607 | 0.010 |
Why?
|
| Protein Binding | 1 | 2017 | 9335 | 0.010 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2005 | 141 | 0.010 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2005 | 180 | 0.010 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2005 | 105 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 1156 | 0.010 |
Why?
|
| Disease Progression | 1 | 2021 | 13502 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2005 | 286 | 0.010 |
Why?
|
| Amylases | 2 | 1994 | 169 | 0.010 |
Why?
|
| Liver Regeneration | 1 | 2005 | 213 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2011 | 2838 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 655 | 0.010 |
Why?
|
| Incidence | 2 | 2019 | 21392 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 15840 | 0.010 |
Why?
|
| Prospective Studies | 4 | 2014 | 54303 | 0.010 |
Why?
|
| Hepatitis | 1 | 2005 | 230 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 2 | 1994 | 187 | 0.010 |
Why?
|
| Renal Circulation | 1 | 2003 | 291 | 0.010 |
Why?
|
| Medicare | 2 | 2016 | 6786 | 0.010 |
Why?
|
| Genotype | 1 | 2017 | 12960 | 0.010 |
Why?
|
| Signal Transduction | 3 | 2012 | 23376 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 13630 | 0.010 |
Why?
|
| Crystallization | 1 | 2003 | 533 | 0.010 |
Why?
|
| Prevalence | 1 | 2019 | 15687 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2000 | 5351 | 0.010 |
Why?
|
| Cell Movement | 2 | 2006 | 5206 | 0.010 |
Why?
|
| Heart | 1 | 1995 | 4393 | 0.010 |
Why?
|
| Duodenum | 2 | 1995 | 486 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3775 | 0.010 |
Why?
|
| Transplantation Conditioning | 2 | 1999 | 1588 | 0.010 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 58995 | 0.010 |
Why?
|
| Materials Testing | 1 | 2005 | 862 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 2003 | 465 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2007 | 1548 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2001 | 516 | 0.010 |
Why?
|
| Young Adult | 2 | 2020 | 58741 | 0.010 |
Why?
|
| Cardioplegic Solutions | 1 | 2000 | 122 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2014 | 3736 | 0.010 |
Why?
|
| Fat Necrosis | 1 | 2000 | 60 | 0.010 |
Why?
|
| Luciferases | 1 | 2002 | 716 | 0.010 |
Why?
|
| HIV Infections | 1 | 2006 | 17165 | 0.010 |
Why?
|
| Immunoglobulin Fragments | 1 | 2000 | 85 | 0.010 |
Why?
|
| Episode of Care | 1 | 2000 | 127 | 0.010 |
Why?
|
| Capillary Leak Syndrome | 1 | 1999 | 32 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 2000 | 321 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2007 | 2138 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 21025 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2010 | 4000 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 3726 | 0.010 |
Why?
|
| Algorithms | 1 | 2000 | 13981 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 835 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2011 | 3061 | 0.010 |
Why?
|
| Cattle | 1 | 2005 | 3847 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 2002 | 625 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2005 | 1435 | 0.010 |
Why?
|
| Rehabilitation Centers | 1 | 2000 | 248 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 687 | 0.010 |
Why?
|
| Chimera | 1 | 1999 | 453 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2007 | 3584 | 0.010 |
Why?
|
| Gallbladder | 1 | 2000 | 305 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1999 | 426 | 0.010 |
Why?
|
| Infant | 3 | 1994 | 36060 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 6216 | 0.010 |
Why?
|
| Breast | 1 | 2007 | 1963 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 2282 | 0.010 |
Why?
|
| Lac Operon | 1 | 1997 | 237 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2001 | 1130 | 0.010 |
Why?
|
| Blood Component Transfusion | 1 | 1998 | 141 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1999 | 681 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 1998 | 270 | 0.010 |
Why?
|
| C-Peptide | 1 | 1999 | 433 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1998 | 516 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 1399 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2005 | 1502 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2001 | 1400 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2007 | 4090 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2005 | 1689 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2002 | 2057 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1999 | 606 | 0.010 |
Why?
|
| Chronic Disease | 2 | 2002 | 9287 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1997 | 650 | 0.010 |
Why?
|
| Probability | 1 | 2001 | 2475 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2001 | 1173 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2003 | 2192 | 0.010 |
Why?
|
| Factor VIII | 1 | 1998 | 349 | 0.010 |
Why?
|
| Vena Cava, Superior | 1 | 1996 | 197 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2001 | 1175 | 0.010 |
Why?
|
| Cell Count | 1 | 1999 | 1835 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 1998 | 584 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 4925 | 0.010 |
Why?
|
| Jugular Veins | 1 | 1996 | 211 | 0.010 |
Why?
|
| Plasma | 1 | 1998 | 584 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1998 | 886 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1995 | 573 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 1997 | 595 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1994 | 42063 | 0.010 |
Why?
|
| Fibronectins | 1 | 1998 | 722 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 4463 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2005 | 2629 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1994 | 374 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1999 | 1871 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1998 | 656 | 0.010 |
Why?
|
| Pulmonary Veins | 1 | 1999 | 745 | 0.010 |
Why?
|
| Syndrome | 1 | 2000 | 3280 | 0.010 |
Why?
|
| Placebos | 1 | 1998 | 1668 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1997 | 1071 | 0.010 |
Why?
|
| Autoimmunity | 1 | 2002 | 1370 | 0.010 |
Why?
|
| Anal Canal | 1 | 1996 | 372 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1997 | 661 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2002 | 2934 | 0.010 |
Why?
|
| Fasting | 1 | 2000 | 1603 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1997 | 1089 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 15620 | 0.010 |
Why?
|
| Epithelium | 1 | 1997 | 1605 | 0.010 |
Why?
|
| Hematuria | 1 | 1994 | 233 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1999 | 1765 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1998 | 1157 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 12766 | 0.010 |
Why?
|
| Monitoring, Intraoperative | 1 | 1998 | 942 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1995 | 1975 | 0.010 |
Why?
|
| Constipation | 1 | 1996 | 561 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10446 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2003 | 3047 | 0.010 |
Why?
|
| Cyclosporins | 1 | 1991 | 216 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 1999 | 1380 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1998 | 3157 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 8552 | 0.010 |
Why?
|
| Vaccination | 1 | 2001 | 3361 | 0.000 |
Why?
|
| Postoperative Period | 1 | 1994 | 1818 | 0.000 |
Why?
|
| Lymph Nodes | 1 | 1999 | 3486 | 0.000 |
Why?
|
| Pancreas | 1 | 1995 | 1677 | 0.000 |
Why?
|
| Treatment Failure | 1 | 1994 | 2648 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1998 | 2520 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1997 | 2912 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 2001 | 11152 | 0.000 |
Why?
|
| Stem Cells | 1 | 1999 | 3523 | 0.000 |
Why?
|
| Diabetic Nephropathies | 1 | 1994 | 988 | 0.000 |
Why?
|
| Ischemia | 1 | 1995 | 1893 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1997 | 4219 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1995 | 1506 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 12965 | 0.000 |
Why?
|
| Contrast Media | 1 | 1995 | 5305 | 0.000 |
Why?
|
| Acute Disease | 1 | 1992 | 7269 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 1995 | 14660 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 1994 | 20080 | 0.000 |
Why?
|